



Press release :

Namur and Gosselies, May 10th 2009.

A new platform for DNA microarrays experimentation, data analysis and data interpretation.

BioXpr SA, a cutting-edge bioinformatics company, and **DNA Vision**, the leading European genetic analysis service company are delighted to announce that they are joining forces to offer pharmaceuticals and red biotech industries a global and seamless service in genetic analyses.

Nowadays the R&D activities of the pharmaceuticals and red biotech industries rely more and more heavily on DNA-based technologies to decipher the causes and the mechanisms of diseases, to uncover the mode of action of drugs, to evaluate the efficacy and safety of new drugs candidate compounds, to discover and monitor relevant disease-associated biomarkers or to predict patients response to drug treatments.

The collaborative effort will revolved around microarrays, miRNA and Next Generation sequencing.

The first joint service being launched seamlessly covers the design, the experimentation, the analysis and interpretation of microarray projects.

Jean-Pol Detiffe, CEO and Co-founder of **DNA Vision**, comments: *"We are very excited by the new opportunities which will undoubtedly be generated by this collaboration. In the current stormy economic situation the pharmaceutical industry is poised more than ever to adopt new R&D stances to tackle the unacceptable ever-increasing drug attrition rate and concentrate on their core activities. Nowadays, a trend in externalizing R&D activities such as microarray projects and associated analysis is observed. With BioXpr, we are positioning ourselves to create an unsurpassed quality biochips platform to further consolidate our positions of first class partners of choice for pharmaceutical and red biotech companies in that field."*

Dr. Benjamin Damien, CEO and Founder of **BioXpr SA**, adds: *"The setting-up of the microarray analysis platform will create an ideal environment to easily intergrate genomics data into Systems Biology. Thanks to our proprietary software modules the customer's gene expression profiling data will be automatically linked to the corresponding relevant impacted signaling pathways. Furthermore the signaling pathways will be dynamically visualized and will be associated with any other available experimental data such as mass spectrometry, Next Gen Sequencing data,... We are confident that this type of dataset integration will support the pharmaceutical and red biotech industries in taking better, quicker and faster decision at any points alongside the whole R&D continuum".*

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision SA, and its subsidiary DNAVision AgriFood SA, offer the powerful combination of different technologies in nucleic acids extraction, expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited, GLP Certified and CLIA-CAP certified).

DNAVision SA is a spin-off of University of Brussels and Institute of Pathology and Genetics. DNAVision AgriFood SA is a spin-off of University of Liège. More information on DNAVision's service portfolio can be found on www.dnavision.be

About BioXpr

BioXpr SA, spin-off from the Namur University, Belgium offer state-of-the-art bioinformatics and biostatistics solutions to collect, store, extract, analyze, compare and translate in value-added knowledge the ever-expanding amount of data generated by today's high-throughput experiments, clinical trials, bio databases and literature. This creates an unmatched high-level business intelligence solution for the pharma and the other Life Science R&D sectors.

In its day-to-day activities BioXpr deal with diverse and wide-ranging sets of data and information, from Next-generation Sequencing to Mass spectrometry, from Microarrays to Protein structure, from bioluminescence to clinical data ...

BioXpr's know-how is based on a library of powerful customizable software modules that can be easily and rapidly combined and integrated to create tailor-made bioinformatics solutions,

BioXpr deliver cross-discipline/transversal software tools integrating and combining literature and experimental data and by doing so play an instrumental role in helping its customers :

- to set up analysis pipelines or data warehousing facilities,
- to detect, predict and monitor multi-component biomarkers for predictive and translational medicine,
- to predict drug candidates efficiency / toxicity on the basis of gene expression and/or activated metabolic pathways
- to design tools and approaches for personalized medicine,
- to build custom, R&D information systems to assist the decision-making process in R&D.

For further info

<u>BioXpr SA</u>	<u>DNAVision</u>
Dr. Benjamin Damien CEO and co-Founder	Jean-Pol Detiffe CEO and co-Founder
Rue du Séminaire, 22 5000 – Namur Belgium	Avenue Georges Lemaître, 25 6041 - Charleroi Belgium
Tel : + 32 81 72 51 55 E-mail : benjamin.damien@bioxpr.be www.bioxpr.com	Tel : + 32 71 34 78 84 E-mail : jp.detiffe@dnavision.be www.dnavision.be